z-logo
Premium
Clinicopathological analysis of the age‐related differences in patients with Epstein–Barr virus (EBV)‐associated extranasal natural killer (NK)/T‐cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection‐associated lymphoproliferative disorders
Author(s) -
Takahashi Emiko,
Ohshima Koichi,
Kimura Hiroshi,
Hara Kazuo,
Suzuki Ritsuro,
Kawa Keisei,
Eimoto Tadaaki,
Nakamura Shigeo
Publication year - 2011
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2011.03976.x
Subject(s) - lymphoma , lymphoproliferative disorders , t cell lymphoma , epstein–barr virus , medicine , natural killer cell , b symptoms , gastroenterology , virus , pathology , immunology , biology , cytotoxic t cell , biochemistry , in vitro
Takahashi E, Ohshima K, Kimura H, Hara K, Suzuki R, Kawa K, Eimoto T & Nakamura S for the NK‐cell Tumor Study Group 
(2011) Histopathology 59 , 660–671 Clinicopathological analysis of the age‐related differences in patients with Epstein–Barr virus (EBV)‐associated extranasal natural killer (NK)/T‐cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection‐associated lymphoproliferative disorders Aims:  Extranodal natural killer (NK)/T‐cell lymphoma (NKTL), comprising nasal NKTL and extranasal NKTL (ENKTL), is associated with Epstein–Barr virus (EBV). A bimodal age distribution was noted in NKTL patients. We examined the clinicopathological differences between two age groups of ENKTL patients ( n  =   23) and compared the findings with those of aggressive NK cell leukaemia (ANKL; n  =   10) and monoclonal chronic active EBV infection‐associated T/NK‐cell lymphoproliferative disorders [chronic active EBV infection/TNK‐lymphoproliferative disorders (CAEBV/TNK‐LPD)] of NK‐cell type ( n  =   45). Methods and results:  Distinct differences existed between elderly (>50 years; n  =   13) and younger (≤50 years; n  =   10) ENKTL patients; the latter showed a higher disease stage ( P  =   0.0286), worse performance status ( P  =   0.0244), more frequent B symptoms ( P  =   0.0286) and more frequent liver, spleen and bone marrow involvement ( P  =   0.0222, 0.0005 and 0.0259, respectively). Few clinicopathological differences existed between younger ENKTL and ANKL patients. Patients with monoclonal CAEBV/TNK‐LPD of NK‐cell type ( n  =   45) showed features similar to those in younger ENKTL/ANKL patients, except a more juvenile onset of CAEBV‐related symptoms and better prognosis. However, the onset age of overt leukaemia/lymphoma in CAEBV/TNK‐LPD patients and overall survival thereafter were similar to those in younger ENKTL/ANKL patients. Conclusions:  ENKTL (≤50 years) is distinct from that in elderly patients and may encompass ANKL and overlap in the clinicopathological profile with NK‐cell type CAEBV/TNK‐LPD.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom